Citius Pharmaceuticals, Inc. 8-K

What Happened

• Citius Pharmaceuticals (CTXR) filed a Form 8‑K on March 31, 2026 (Item 8.01) reporting that its majority‑owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), issued a press release announcing a commercial update on the U.S. launch of LYMPHIR™ (denileukin diftitox‑cxdl). The press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Date of filing/announcement: March 31, 2026.
• Subsidiary/ticker: Citius Oncology, Inc. (Nasdaq: CTOR) — majority‑owned by Citius Pharmaceuticals.
• Product: LYMPHIR™ (denileukin diftitox‑cxdl) — commercial launch update announced.
• Document filed: Press release attached as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• This 8‑K signals a commercial step for LYMPHIR in the U.S., which is directly relevant to potential future product revenue and commercial progress for the company’s oncology business. Investors should watch for follow‑up disclosures (sales data, reimbursement updates, launch milestones) from CTOR or CTXR that provide measurable financial impact. The filing itself is informational—no financial results or new material agreements were reported in this Form 8‑K.